Sandoz's $478.5M Price-Fixing Settlement: What Clinicians Must Know

References

1. 1.Silverman, E. (2026, August 3). Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states. STAT News. https://www.statnews.com/pharmalot/2026/08/03/sandoz-to-settle-price-fixing-allegations/
2. 2.Dusetzina, S. B., Besaw, R. J., & Higashi, A. S. (2022). Out-of-pocket costs and medication adherence among patients with chronic conditions in the United States. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2022.1209
3. 3.Khera, R., Valero-Elizondo, J., & Nasir, K. (2021). Financial toxicity in atherosclerotic cardiovascular disease in the United States: current state and future directions. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.120.050268
4. 4.Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016). The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA, 316(8), 858–871. https://doi.org/10.1001/jama.2016.11237
5. 5.Australian Government Department of Health and Aged Care. (2023). Pharmaceutical Benefits Scheme: Overview of PBS pricing and policy. Australian Government. https://www.health.gov.au/topics/drugs-and-controlled-substances/pharmaceutical-benefits-scheme
6. 6.Patel, M. R., Piette, J. D., Resnicow, K., Kowalski-Dobson, T., & Heisler, M. (2016). Social determinants of health, cost-related nonadherence, and cost-reducing behaviors among adults with diabetes. Medical Care, 54(8), 796–803. https://doi.org/10.1097/MLR.0000000000000537
7. 7.Feldman, R., & Wang, E. (2021). A new pharmaceutical market structure: the generic drug problem. American Journal of Law and Medicine, 47(2–3), 191–213. https://doi.org/10.1017/amj.2021.19
8. 8.Vitry, A., & Roughead, E. (2022). Managed entry agreements for medicines in Australia: an updated review. PharmacoEconomics, 40(9), 845–857. https://doi.org/10.1007/s40273-022-01145-4